✦ LIBER ✦

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

✍ Scribed by Ronald Pruitt; John Hanson; Michael Safdi; Lawrence Wruble; Robert Hardi; John Johanson; George Koval; Dennis Riff; Barry Winston; Amanda Cross; Pamela Doty; Lorin K Johnson

Book ID: 119393713
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 158 KB
Volume: 97
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(02)05520-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Balsalazide is superior to mesalamine in

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis

✍ Ronald Pruitt; John Hanson; Michael Safdi; Lawrence Wruble; Robert Hardi; John F 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 345 KB

T1152 Balsalazide Tablets 3.3g Twice Dai

T1152 Balsalazide Tablets 3.3g Twice Daily Improves Signs and Symptoms of Mild-to-Moderate Ulcerative Colitis

✍ Bosworth, Brian P.; Pruitt, Ronald E.; Gordon, Glenn L.; Lamet, Mark; Shaw, Audr 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Effect of extended MMX mesalamine therap

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis

✍ Michael A. Kamm; Gary R. Lichtenstein; William J. Sandborn; Stefan Schreiber; Ki 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 259 KB

Background: Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies. This study aimed to determine the effect of 8 weeks' high-dose MMX mesalamine extensi

A randomized, double blind, dose-respons

A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis

✍ Douglas S Levine; Dennis S Riff; Ronald Pruitt; Lawrence Wruble; George Koval; D 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 307 KB

T1196 Twice-Daily Dosing of Balsalazide

T1196 Twice-Daily Dosing of Balsalazide Tablets 3.3 G Is Safe and Effective in the Treatment of Mild-to-Moderate Ulcerative Colitis

✍ Scherl, Ellen J.; Pruitt, Ron E.; Gordon, Glenn L.; Lamet, Mark; Shaw, Audrey L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 94 KB

T1140 A Comparison of Different Definiti

T1140 A Comparison of Different Definitions for Measuring the Time to Initial Symptom Resolution in Active, Mild-to-Moderate Ulcerative Colitis

✍ Sandborn, William J.; Lichtenstein, Gary R.; Karlstadt, Robyn G.; Barrett, Karen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 202 KB